Anixa Biosciences Receives Notice of Allowance from Canadian Intellectual Property Office for Patent Covering Breast Cancer Vaccine Technology
Anixa Biosciences (NASDAQ: ANIX) has received a Notice of Allowance from the Canadian Intellectual Property Office for a patent covering its breast cancer vaccine technology. The patent, exclusively licensed from Cleveland Clinic, provides composition-of-matter protection for their novel immunogenic approach in Canada.
The vaccine targets human α-lactalbumin, a protein expressed during lactation and in certain breast cancers. This technology addresses a significant market need, as breast cancer represents 25% of new cancer cases in Canadian women and 13% of female cancer deaths annually. The patent strengthens Anixa's international intellectual property portfolio and supports future regulatory and commercial efforts outside the U.S.
Anixa Biosciences (NASDAQ: ANIX) ha ricevuto un Avviso di Concessione dall'Ufficio Canadese della Proprietà Intellettuale per un brevetto che copre la sua tecnologia per il vaccino contro il cancro al seno. Il brevetto, concesso in licenza esclusiva dalla Cleveland Clinic, offre protezione sulla composizione della materia per il loro innovativo approccio immunogenico in Canada.
Il vaccino è mirato contro l'α-lattalbumina umana, una proteina espressa durante l'allattamento e in alcuni tipi di cancro al seno. Questa tecnologia risponde a una significativa esigenza di mercato, dato che il cancro al seno rappresenta il 25% dei nuovi casi di cancro nelle donne canadesi e il 13% dei decessi femminili per cancro ogni anno. Il brevetto rafforza il portafoglio internazionale di proprietà intellettuale di Anixa e supporta i futuri sforzi regolatori e commerciali al di fuori degli Stati Uniti.
Anixa Biosciences (NASDAQ: ANIX) ha recibido un Aviso de Concesión por parte de la Oficina Canadiense de Propiedad Intelectual para una patente que cubre su tecnología de vacuna contra el cáncer de mama. La patente, licenciada exclusivamente por la Cleveland Clinic, proporciona protección de composición de materia para su novedoso enfoque inmunogénico en Canadá.
La vacuna está dirigida a la α-lactalbúmina humana, una proteína expresada durante la lactancia y en ciertos cánceres de mama. Esta tecnología responde a una necesidad importante del mercado, ya que el cáncer de mama representa el 25% de los nuevos casos de cáncer en mujeres canadienses y el 13% de las muertes femeninas por cáncer anualmente. La patente fortalece la cartera internacional de propiedad intelectual de Anixa y respalda futuros esfuerzos regulatorios y comerciales fuera de los EE. UU.
Anixa Biosciences (NASDAQ: ANIX)가 캐나다 지식재산청으로부터 유방암 백신 기술에 대한 특허 허가 통지를 받았습니다. 이 특허는 Cleveland Clinic으로부터 독점 라이선스를 받은 것으로, 캐나다 내에서 그들의 혁신적인 면역원성 접근법에 대한 조성물 보호를 제공합니다.
이 백신은 수유 중 및 특정 유방암에서 발현되는 인간 α-락탈부민 단백질을 표적으로 합니다. 이 기술은 유방암이 캐나다 여성의 신규 암 사례의 25%와 여성 암 사망의 13%를 차지하는 중요한 시장 수요를 해결합니다. 이 특허는 Anixa의 국제 지식재산 포트폴리오를 강화하며 미국 외 지역에서의 향후 규제 및 상업적 노력을 지원합니다.
Anixa Biosciences (NASDAQ : ANIX) a reçu un avis d'acceptation de l'Office de la propriété intellectuelle du Canada pour un brevet couvrant sa technologie de vaccin contre le cancer du sein. Ce brevet, licencié exclusivement par la Cleveland Clinic, offre une protection de composition pour leur nouvelle approche immunogénique au Canada.
Le vaccin cible l'α-lactalbumine humaine, une protéine exprimée pendant la lactation et dans certains cancers du sein. Cette technologie répond à un besoin important du marché, le cancer du sein représentant 25 % des nouveaux cas de cancer chez les femmes canadiennes et 13 % des décès féminins par cancer chaque année. Ce brevet renforce le portefeuille international de propriété intellectuelle d'Anixa et soutient les futurs efforts réglementaires et commerciaux en dehors des États-Unis.
Anixa Biosciences (NASDAQ: ANIX) hat vom Canadian Intellectual Property Office eine Zulassungsmitteilung für ein Patent erhalten, das ihre Technologie für einen Brustkrebsimpfstoff abdeckt. Das Patent, exklusiv von der Cleveland Clinic lizenziert, bietet in Kanada einen Schutz für die Zusammensetzung ihrer neuartigen immunogenen Methode.
Der Impfstoff richtet sich gegen das humane α-Laktalbumin, ein Protein, das während der Stillzeit und bei bestimmten Brustkrebserkrankungen exprimiert wird. Diese Technologie deckt einen bedeutenden Marktbedarf ab, da Brustkrebs 25 % der neuen Krebsfälle bei kanadischen Frauen und 13 % der Krebstodesfälle bei Frauen jährlich ausmacht. Das Patent stärkt das internationale geistige Eigentumsportfolio von Anixa und unterstützt zukünftige regulatorische und kommerzielle Bemühungen außerhalb der USA.
- Secured patent protection in Canada for breast cancer vaccine technology
- Expands international IP portfolio in key markets with high breast cancer incidence
- Addresses unmet medical need with no current approved breast cancer vaccine
- Exclusive license from Cleveland Clinic strengthens competitive position
- Early-stage technology still requiring clinical development
- Commercialization timeline and regulatory approval uncertain
Insights
Anixa's Canadian patent allowance strengthens global IP protection for its novel breast cancer vaccine, enhancing commercialization potential in key markets.
The Canadian Intellectual Property Office's Notice of Allowance for Anixa's breast cancer vaccine technology represents a significant IP milestone that extends composition-of-matter protection to another major market. This patent, licensed from Cleveland Clinic, secures exclusive rights to their innovative α-lactalbumin-targeting approach in Canada, where breast cancer accounts for approximately
The strategic value of this patent extends beyond simple geographic expansion. Canada represents a sophisticated pharmaceutical market with robust regulatory standards and serves as a potential gateway to other international markets. Composition-of-matter patents offer the strongest form of protection, covering the actual molecular components of the vaccine rather than just methods of use.
This patent allowance enhances Anixa's competitive positioning in two critical ways: First, it creates barriers to entry for potential competitors in a country with high breast cancer prevalence. Second, it increases the company's attractiveness for potential partnerships or licensing deals with global pharmaceutical companies seeking to expand their oncology portfolios.
The timing is particularly valuable as Anixa progresses its clinical development program in the US. Building a comprehensive international patent estate before late-stage clinical trials significantly strengthens negotiating positions with potential commercialization partners and protects market exclusivity during the crucial early commercialization years.
While still in clinical development, securing this protection in a market with significant unmet need (no approved breast cancer prevention vaccines) positions Anixa to potentially capture substantial value if their α-lactalbumin targeting approach proves successful in trials.
Patent Strengthens International Protection for First-of-Its-Kind Immunopreventive Platform
Expands Global IP Coverage in Markets with High Incidence of Breast Cancer
With this allowance, Anixa continues to expand the international scope of its intellectual property portfolio, reinforcing its leadership in the field of cancer immunoprevention. The Canadian patent complements issued and pending patents in
"This newly allowed patent further illustrates the international recognition of the novelty and potential of our breast cancer vaccine," stated Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences. "As we continue advancing clinical development in the
Breast cancer remains the most commonly diagnosed cancer in women globally and a leading cause of cancer-related death. In
Anixa's vaccine is based on immunizing against human α-lactalbumin, a protein associated with lactation that is aberrantly expressed in certain types of breast cancer. This "retired" protein strategy, developed at Cleveland Clinic and licensed exclusively to Anixa, aims to selectively prime the immune system to prevent tumor formation while avoiding harm to normal tissue.
By reinforcing its global patent estate, Anixa is laying the groundwork for future international development and commercialization strategies. The Company's broader vaccine platform also targets other high-incidence cancers and is designed to transform how the medical community approaches cancer prevention.
About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. This technology is differentiated from other cell therapies as the natural ligand of the FSHR receptor, FSH, binds to the FSHR receptor on the tumor cell instead of an antibody fragment. Moffitt is a world leader in cancer immunotherapy treatments, pioneering next-generation cell therapies such as CAR-T, and tumor infiltrating lymphocytes (TILs) to harness the power of the immune system. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. The breast and ovarian cancer vaccines were developed at Cleveland Clinic and exclusively licensed to Anixa. Cleveland Clinic is entitled to royalties and other commercialization revenues from the Company related to these vaccine technologies. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on LinkedIn, X, Facebook and YouTube.
Forward-Looking Statements
Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.
Contact:
Mike Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808
View original content to download multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-receives-notice-of-allowance-from-canadian-intellectual-property-office-for-patent-covering-breast-cancer-vaccine-technology-302516540.html
SOURCE Anixa Biosciences, Inc.
FAQ
What is the significance of Anixa Biosciences' (NASDAQ: ANIX) new Canadian patent?
How does Anixa's breast cancer vaccine technology work?
What is the market opportunity for Anixa's breast cancer vaccine in Canada?
Who developed the breast cancer vaccine technology licensed by Anixa?
What stage of development is Anixa's breast cancer vaccine currently in?
